Загрузка...
Cost-effectiveness of Interferon-free therapy for Hepatitis C in Germany - an application of the efficiency frontier approach
BACKGROUND: The approval of direct-acting antivirals for Interferon-free treatment revolutionized the therapy of chronic Hepatitis C infection. As of August 2014, two treatment regimens for genotype 1 infection received conditional approval in the European Union: Sofosbuvir and Ribavirin for 24 week...
Сохранить в:
| Опубликовано в: : | BMC Infect Dis |
|---|---|
| Главные авторы: | , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
BioMed Central
2015
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4520276/ https://ncbi.nlm.nih.gov/pubmed/26223310 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12879-015-1048-z |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|